Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock BCRX Nasdaq Global Select Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________________ to ...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants John Bluth - Investor Relations Jon Stonehouse - Chief Executive Officer Anthony Doyle - Chief Financial Officer Charlie Gayer - Chief Commercial Officer Helen Thackray - Chief R&D Officer Conference Call Participants Tazeen Ahmad - Bank of America Stacy Ku - Cowen & Co. Jon Wolleben - JMP Securities Justin Kim - Oppenheimer & Co. Inc. Serge Belanger - Needham & Company Operator Good ...

Financial Performance & Guidance - BioCryst's cash, cash equivalents, restricted cash & investments decreased from $444 million at the end of 2022 to $416 million as of June 30, 2023[9] - The company anticipates ORLADEYO® revenue to be greater than or equal to $320 million for the full year 2023[10] - Operating expenses, excluding non-cash compensation, are projected to be $375 million for 2023[10] Debt Financing - BioCryst secured a $450 million financing agreement with Pharmakon Advisors, with $300 million drawn at issuance[10] - An additional $150 million is available to draw through September 2024[8, 10] - The interest rate is 3-month SOFR + 700%, with a PIK option of +725%[8] - 50% of the interest for the first six quarters can be paid in kind (PIK)[8, 10] - The new terms include no financial covenants, compared to the prior terms which required a minimum liquidity of $15 million[8] ORLADEYO® & Pipeline Updates - A pediatric trial is ongoing to evaluate a new granule formulation of ORLADEYO® for children with HAE aged 2 to under 12[4, 5, 6] - The trial aims to enroll approximately 20 patients across 4 cohorts[6]

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock BCRX Nasdaq Global Select Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________________ to ...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2023 Earnings Conference Call May 3, 2023 8:30 AM ET Company Participants John Bluth - Investor Relations Jon Stonehouse - Chief Executive Officer Anthony Doyle - Chief Financial Officer Charlie Gayer - Chief Commercial Officer Helen Thackray - Chief R&D Officer Conference Call Participants Allison Bratzel - Piper Sandler Jon Wolleben - JMP Securities Tazeen Ahmad - Bank of America Stacy Ku - Cowen & Co. Justin Kim - Oppenheimer & Co. Inc. Serge Belanger - Nee ...

First Quarter 2023 Results Call Corporate Update & Financial Results May 3, 2023 Forward-Looking Statements BioCryst's presentation may contain forward-looking statements, including statements regarding future results, unaudited and forward-looking financial information and company performance or achievements. These statements are subject to known and unknown risks and uncertainties which may cause our actual results, performance or achievements to be materially different from any future results or performa ...

1 J.P. MORGAN HEALTHCARE CONFERENCE JON STONEHOUSE PRESIDENT AND CHIEF EXECUTIVE OFFICER JANUARY 2023 ForwardLooking Statements BioCryst's presentation may contain forward-looking statements, including statements regarding future results, unaudited and forward-looking financial information and company performance or achievements. These statements are subject to known and unknown risks and uncertainties which may cause our actual results, performance or achievements to be materially different from any future ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 par value BCRX Nasdaq Global Select Market Large accelerated filer x Accelerated filer o Non-accelerated filer oSmaller reporting company o Emerging growth company o UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 o TRANSITION RE ...

Fourth Quarter 2022 Results Call Corporate Update & Financial Results February 21, 2023 Forward-Looking Statements BioCryst's presentation may contain forward-looking statements, including statements regarding future results, unaudited and forward-looking financial information and company performance or achievements. These statements are subject to known and unknown risks and uncertainties which may cause our actual results, performance or achievements to be materially different from any future results or p ...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2022 Earnings Conference Call February 21, 2023 8:30 AM ET Company Participants John Bluth - Investor Relations Jon Stonehouse - Chief Executive Officer Anthony Doyle - Chief Financial Officer Charlie Gayer - Chief Commercial Officer Helen Thackray - Chief R&D Officer Conference Call Participants Jessica Fye - JPMorgan Tazeen Ahmad - Bank of America Chris Raymond - Piper Sandler Liisa Bayko - Evercore ISI Jon Wolleben - JMP Securities Ken Cacciatore - Cowen & ...